Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer

December 14th 2019

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC

December 14th 2019

The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.

Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes

December 14th 2019

Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.

Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer

December 13th 2019

The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.

Estrogen Decreases Breast Cancer Incidence in Postmenopausal Women, Estrogen Plus Progestin Has Opposite Effect

December 13th 2019

Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.

Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer

December 13th 2019

Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.

Neoadjuvant Durvalumab Regimen Shows Promise in TNBC

December 13th 2019

A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.

Dr. Conte on the OlympiAD Trial in BRCA-Mutated HER2-Negative Breast Cancer

December 13th 2019

Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.

Accelerated Partial Breast Irradiation Could Replace Whole Breast Irradiation in Low-Risk Early Breast Cancer

December 13th 2019

Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.

Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC

December 13th 2019

Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with BRCA-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial.

Neoadjuvant Atezolizumab Regimen Slightly Improves pCR in TNBC

December 13th 2019

Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,

Survival Benefit Hinted at With Durvalumab Maintenance in TNBC

December 13th 2019

Maintenance durvalumab may improve outcomes versus chemotherapy in patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, according to exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.

Anastrozole Maintains Breast Cancer Prevention Effect in Long-Term Follow-Up

December 12th 2019

The aromatase inhibitor anastrozole maintained a preventive effect for postmenopausal women at high risk for breast cancer nearly 12 years after discontinuing treatment.

Benefit in pCR Rates Are Achieved With Pembrolizumab in Early TNBC

December 12th 2019

Patients with triple-negative breast cancer have greater rates of pathologic complete responses when pembrolizumab is added to neoadjuvant and adjuvant chemotherapy. Furthermore, these benefits are observed across patient subgroups, most notably in those patients with stage III and/or node-positive disease.

Palbociclib Real-World Results Indicate OS Benefit in Frontline HR+/HER2- Breast Cancer

December 12th 2019

Real-world data for frontline palbociclib indicate that the positive progression-free survival data observed with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival benefit in patients with HR-positive/HER2-negative metastatic breast cancer

Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer

December 12th 2019

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.

S-1 Improves iDFS in HR+, HER2- Breast Cancer

December 12th 2019

Adding the novel oral fluoropyrimidine derivative S-1 to adjuvant endocrine therapy significantly improved invasive disease-free survival for Japanese patients with HR-positive, HER2-negative breast cancer.

FDA Approves Generic Everolimus Tablets

December 11th 2019

The FDA has approved 2 abbreviated new drug applications for everolimus (Afinitor) tablets for the treatment of patients with select malignancies.

Precision Medicine Propels Research Efforts in Breast Cancer

December 5th 2019

Mark E. Robson, MD, provides a snapshot of the precision focus in breast cancer, as well as the emergence of biosimilars in the field.

Sacituzumab Govitecan TNBC Application Resubmitted to FDA

December 4th 2019

Immunomedics has resubmitted its biologics license application to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease.